title: [Treatment of ileus and carcinomatous peritonitis].
abstract: In patients with carcinomatous peritonitis caused by the invasion and peritoneal dissemination of gastrointestinal cancer, disease progression can trigger complications such as ileus, ascites, and hydronephrosis.Anorexia, impaired oral intake, nausea, vomiting, abdominal pain, abdominal bloating, anuria, and other symptoms can develop, negatively affecting patients' general condition and quality of life.The treatment of carcinomatous peritonitis is an important determinant of outcomes, but the guidelines for its diagnosis, the evaluation of its response to chemotherapy, and the question of which standard therapy to apply remain unestablished.In recent years, however, clinical trials have attempted to evaluate the benefits of systemic chemotherapy and the intraperitoneal administration of drugs such as cisplatin and paclitaxel in patients with advanced or recurrent gastric cancer who have peritoneal dissemination.In the field of palliative therapy, octreotide has been approved in Japan for the amelioration of symptoms associated with gastrointestinal obstruction.Such treatment is expected to contribute substantially to improving patients' quality of life.
authors.affiliation: Dept. of Gastroenterology, Kitasato University School of Medicine, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Ishido
authors.forename: Wasaburo
authors.initials: W
authors.lastname: Koizumi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tanabe
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Higuchi
authors.forename: Tohru
authors.initials: T
authors.lastname: Sasaki
authors.forename: Chikatoshi
authors.initials: C
authors.lastname: Katada
authors.forename: Mizutomo
authors.initials: M
authors.lastname: Azuma
authors.forename: Akira
authors.initials: A
authors.lastname: Naruke
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D045823:Ileus / Q000209:etiology / Q000628:therapy*; D009369:Neoplasms / Q000150:complications*; D010538:Peritonitis / Q000209:etiology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents